Public Health Webinar Series on Blood Disorders

Public Health Webinar Series on Blood Disorders: Bringing Science Into Practice

CDC’s Division of Blood Disorders (DBD) is proud to offer its Public Health Webinar Series on Blood Disorders. The purpose of this series is to provide evidence-based information on new research, interventions, emerging issues of interest in blood disorders, as well as innovative approaches in collaborations and partnerships. We invite you to join us in this series.

Archives for 2021

Claire McLintock

October 12, 2021

Claire McLintock, MD, FRACP, FRCPA, ONZM (moderator)
National Women’s Health
Auckland City Hospital, Auckland, New Zealand

Alex C. Spyropoulos

Alex Spyropoulos, MD, FACP, FCCP, FRCPC
Northwell Health, New York City, New York

Alok A. Khorana

Alok A. Khorana, MD, FACP, FASCO
Cleveland Clinic, Cleveland, Ohio

Beverley Hunt

Prof. Beverley Hunt, MD, OBE
King’s College, London, England

Clotting Risks During Hospitalization: Exploring General Thromboprophylaxis and Special Casesexternal icon

This webinar, co-hosted by the International Society on Thrombosis and Haemostasis and the Centers for Disease Control (Division of Blood Disorders), provides an overview on clotting risks during hospitalization.


Raj Kasthuri, MBBS

August 19, 2021

Raj Kasthuri, MBBS
Professor of Medicine, Division of Hematology
Director of the UNC Hereditary Hemorrhagic Telangiectasia Center of Excellence
Associate Director for Clinical Research,
UNC Blood Research Center
University of North Carolina at Chapel Hill

Hanny Al-Samkari, MD

Hanny Al-Samkari, MD
Assistant Professor of Medicine, Harvard Medical School
Classical Hematologist and Clinical Investigator,
Division of Hematology Oncology
Massachusetts General Hospital
Associate Director of the Massachusetts General Hospital Hereditary Hemorrhagic Telangiectasia Center of Excellence
Boston, Massachusetts

Hereditary Hemorrhagic Telangiectasia in 2021: Diagnosis and Advances in Treatmentexternal icon

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is an autosomal dominant bleeding disorder due to abnormal blood vessel formation affecting approximately 1 in 5,000 individuals. Diagnosis and management of HHT can be challenging and requires a multidisciplinary approach.

In this webinar, Dr. Kasthuri and Dr. Al-Samkari discuss various aspects of HHT including inheritance, clinical manifestations, approach to diagnosis, screening and management. The prevalence of anemia in the HHT population and challenges with its management that are unique to HHT will be emphasized, as will the emergence of systemic therapies to treat bleeding. In particular, systemic antiangiogenic treatments that are changing the treatment landscape of HHT will be highlighted. Additionally, the recently published Second International Guidelines for the Diagnosis and Treatment of HHT will be reviewed and discussed.


Dr. Alexis Thompson

June 24, 2021

Alexis A. Thompson, MD, MPH
Hematology Section Head
A. Watson and Sarah Armour Endowed Chair for Blood Diseases and Cancer

Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics, Northwestern University Feinberg School of Medicine

Associate Director for Equity and Minority Health
Robert H. Lurie Comprehensive Cancer Center and Northwestern University Feinberg School of Medicine

Bone Marrow Transplantation and Other Curative Approaches in Thalassemiaexternal icon

The thalassemia syndromes are a group of genetic blood disorders in which the production of one of the two different globin proteins (alpha or beta) that make up hemoglobin is reduced or absent. The result is anemia due to both ineffective erythropoiesis and chronic hemolysis, which typically begins in early childhood and lasts throughout life.

The clinical severity of thalassemia and interventions needed depend upon the globin chain affected and the type of genetic mutation. Persons with the most severe forms of thalassemia often require regular transfusions to treat the anemia and chelation therapy to prevent iron overload and associated sequelae. However, many patients with transfusion-dependent thalassemia (TDT) have struggled with adherence to the ongoing, intensive treatment regimen. Recent innovations, such as oral iron chelation agents, have helped improve adherence, and thus, prognoses (i.e., survival and quality of life in persons with TDT). Nonetheless, some patients and families are interested in definitive, potentially curative treatments.

In this webinar, Dr. Thompson describes considerations for stem cell transplantation, including patient characteristics, donor stem cell sources, and preparative regimens that impact clinical outcomes. She provides an overview of genomic therapies, such as gene addition and gene editing, and reviews the results of clinical studies on thalassemia.


Rachel P. Rosovsky, MD, MPH

March 11, 2021

Rachel P. Rosovsky, MD, MPH
Director, Thrombosis Research, Division of Hematology,
Massachusetts General Hospital

Assistant Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Multidisciplinary Care for Acute Pulmonary Embolism: The Pulmonary Embolism Response Teamexternal icon

Pulmonary embolism (PE) is a major cause of morbidity and mortality in the United States, accounting for up to 100,000 deaths annually. Although there has been a surge of new therapeutic tools and strategies designed to treat patients with PE, the outcomes for patients who present with massive or high-risk PE remain dismal.

In this webinar, Rachel Rosovsky, MD, discusses the model and purpose of pulmonary embolism response teams (PERT), presents the structure and organization, examines evidence for efficacy and usefulness, and shares the mission of the PERT Consortium. She also discusses future directions for research that will help evaluate the value of this innovative model and determine if this collaborative approach improves PE outcomes, improves clinical care, is cost effective, enriches patients’ quality of life, and advances the science of PE treatment.


Jean Grow, PhD

February 25, 2021 

Jean Grow, PhD
Professor of Advertising, Emeritus, and Co-Director of the Institute for Women’s Leadership
Marquette University
Milwaukee, Wisconsin

Nathan T. Connell, MD, MPH

Nathan T. Connell, MD, MPH
Assistant Professor of Medicine, Harvard Medical School
Associate Physician in the Hematology Division
Brigham and Women’s Hospital
Boston, Massachusetts

Angela Weyand, MD

Angela Weyand, MD
Assistant Professor of Pediatric Hematology and Oncology
University of Michigan
Ann Arbor, Michigan

Joint Guidelines on the Diagnosis and Management of von Willebrand Disease external icon

The American Society of Hematology (ASH), International Society on Thrombosis and Hemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) came together to develop updated clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD). In this webinar, three of the guideline development panelists, Jean Grow, PhD, Nathan Connell, MD, MPH, and Angela Weyand, MD, present key recommendations from the guidelines, the process through which they were developed, and implications for the improved diagnosis and management of people with VWD.


For more information on the webinar series, please contact Cindy Sayers at cay1@cdc.gov.